Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer

Circulating tumor DNA (ctDNA) has recently emerged as a real-time prognostic and predictive biomarker for monitoring cancer patients. Here, we aimed to ascertain whether tumor-agnostic ctDNA testing would be a feasible strategy to monitor disease progression and therapeutic response in muscle-invasi...

Descripción completa

Detalles Bibliográficos
Autores: Carrasco, Raquel, Ingelmo-Torres, Mercedes, Trullas, Ramón, Roldán, Fiorella L., Rodríguez-Carunchio, Leonardo, Juez, Lourdes, Sureda, Joan, Alcaraz, Antonio, Mengual, Lourdes, Izquierdo, Laura
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/340188
Acceso en línea:http://hdl.handle.net/10261/340188
Access Level:acceso abierto
Palabra clave:Bladder cancer
Circulating tumor DNA
Droplet digital PCR
Prognosis
id ES_42e5e7700a035c29c46f31e28071d500
oai_identifier_str oai:digital.csic.es:10261/340188
network_acronym_str ES
network_name_str España
repository_id_str
spelling Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder CancerCarrasco, RaquelIngelmo-Torres, MercedesTrullas, RamónRoldán, Fiorella L.Rodríguez-Carunchio, LeonardoJuez, LourdesSureda, JoanAlcaraz, AntonioMengual, LourdesIzquierdo, LauraBladder cancerCirculating tumor DNADroplet digital PCRPrognosisCirculating tumor DNA (ctDNA) has recently emerged as a real-time prognostic and predictive biomarker for monitoring cancer patients. Here, we aimed to ascertain whether tumor-agnostic ctDNA testing would be a feasible strategy to monitor disease progression and therapeutic response in muscle-invasive bladder cancer (MIBC) patients after radical cystectomy (RC). Forty-two MIBC patients who underwent RC were prospectively included. Blood samples from these patients were collected at different follow-up time points. Two specific mutations (TERT c.1-124C>T and ATM c.1236-2A>T) were analyzed in the patients’ plasma samples by droplet digital PCR to determine their ctDNA status. During a median follow-up of 21 months, 24% of patients progressed in a median of six months. ctDNA status was identified as a prognostic biomarker of tumor progression before RC and 4 and 12 months later (HR 6.774, HR 3.673, and HR 30.865, respectively; p < 0.05). Lastly, dynamic changes in ctDNA status between baseline and four months later were significantly associated with patient outcomes (p = 0.045). In conclusion, longitudinal ctDNA analysis using a tumor-agnostic approach is a potential tool for monitoring MIBC patients after RC. The implementation of this testing in a clinical setting could improve disease management and patients’ outcomes.This research was funded by the Instituto de Salud Carlos III (ISCIII) through the Plan Estatal de Investigación Científica y Técnica y de Innovación 2021–2023 (project reference number PI20/00409) and co-funded by the European Regional Development Fund (FEDER).Peer reviewedMultidisciplinary Digital Publishing InstituteInstituto de Salud Carlos IIIEuropean CommissionCarrasco, Raquel [0000-0002-2792-5316]Trullas, Ramón [0000-0001-7951-9881]Mengual, Lourdes [0000-0001-7418-9422]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2023202320232023info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/340188reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)InglésThe underlying dataset has been published as supplementary material of the article in the publisher platform at https://doi.org/10.3390/ijms242316578https://doi.org/10.3390/ijms242316578Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3401882026-05-22T06:33:51Z
dc.title.none.fl_str_mv Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer
title Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer
spellingShingle Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer
Carrasco, Raquel
Bladder cancer
Circulating tumor DNA
Droplet digital PCR
Prognosis
title_short Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer
title_full Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer
title_fullStr Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer
title_full_unstemmed Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer
title_sort Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer
dc.creator.none.fl_str_mv Carrasco, Raquel
Ingelmo-Torres, Mercedes
Trullas, Ramón
Roldán, Fiorella L.
Rodríguez-Carunchio, Leonardo
Juez, Lourdes
Sureda, Joan
Alcaraz, Antonio
Mengual, Lourdes
Izquierdo, Laura
author Carrasco, Raquel
author_facet Carrasco, Raquel
Ingelmo-Torres, Mercedes
Trullas, Ramón
Roldán, Fiorella L.
Rodríguez-Carunchio, Leonardo
Juez, Lourdes
Sureda, Joan
Alcaraz, Antonio
Mengual, Lourdes
Izquierdo, Laura
author_role author
author2 Ingelmo-Torres, Mercedes
Trullas, Ramón
Roldán, Fiorella L.
Rodríguez-Carunchio, Leonardo
Juez, Lourdes
Sureda, Joan
Alcaraz, Antonio
Mengual, Lourdes
Izquierdo, Laura
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Instituto de Salud Carlos III
European Commission
Carrasco, Raquel [0000-0002-2792-5316]
Trullas, Ramón [0000-0001-7951-9881]
Mengual, Lourdes [0000-0001-7418-9422]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Bladder cancer
Circulating tumor DNA
Droplet digital PCR
Prognosis
topic Bladder cancer
Circulating tumor DNA
Droplet digital PCR
Prognosis
description Circulating tumor DNA (ctDNA) has recently emerged as a real-time prognostic and predictive biomarker for monitoring cancer patients. Here, we aimed to ascertain whether tumor-agnostic ctDNA testing would be a feasible strategy to monitor disease progression and therapeutic response in muscle-invasive bladder cancer (MIBC) patients after radical cystectomy (RC). Forty-two MIBC patients who underwent RC were prospectively included. Blood samples from these patients were collected at different follow-up time points. Two specific mutations (TERT c.1-124C>T and ATM c.1236-2A>T) were analyzed in the patients’ plasma samples by droplet digital PCR to determine their ctDNA status. During a median follow-up of 21 months, 24% of patients progressed in a median of six months. ctDNA status was identified as a prognostic biomarker of tumor progression before RC and 4 and 12 months later (HR 6.774, HR 3.673, and HR 30.865, respectively; p < 0.05). Lastly, dynamic changes in ctDNA status between baseline and four months later were significantly associated with patient outcomes (p = 0.045). In conclusion, longitudinal ctDNA analysis using a tumor-agnostic approach is a potential tool for monitoring MIBC patients after RC. The implementation of this testing in a clinical setting could improve disease management and patients’ outcomes.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/340188
url http://hdl.handle.net/10261/340188
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv The underlying dataset has been published as supplementary material of the article in the publisher platform at https://doi.org/10.3390/ijms242316578
https://doi.org/10.3390/ijms242316578
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406979036807168
score 15.811543

Similares en LA Referencia